cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Eyepoint Pharmaceuticals Inc
3 own
13 watching
Current Price
$0
$-0.05
(-1.1%)
logo-eypt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
155.37M
52-Week High
52-Week High
14.41
52-Week Low
52-Week Low
2.19
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization155.37M
icon52-Week High14.41
icon52-Week Low2.19
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Eyepoint Pharmaceuticals Inc do?
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Read More
How much money does Eyepoint Pharmaceuticals Inc make?
News & Events about Eyepoint Pharmaceuticals Inc.
PR Newswire
3days ago
EYEPOINT SHAREHOLDER ACTION REMINDER EYEPOINT SHAREHOLDER ACTION REMINDER PR Newswire NEW YORK, Jan. 28, 2023 Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options NEW YORK, Jan. 28...
Globe Newswire
8days ago
State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 WATERTOWN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical ...
PR Newswire
9days ago
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who...
PR Newswire
23days ago
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who...
Globe Newswire
26days ago
Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021 Cash ...
Frequently Asked Questions
Frequently Asked Questions
What is Eyepoint Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Eyepoint Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Eyepoint Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Eyepoint Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Eyepoint Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Eyepoint Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Eyepoint Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Eyepoint Pharmaceuticals Inc?
plus_minus_icon
What percentage is Eyepoint Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Eyepoint Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.05
(-1.1%)
logo-eypt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00